7 documents found, page 1 of 1
Cost-Effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and P...
Martins, P; Vandewalle, B; Félix, J; Capela, C; Cerqueira, JJ; Salgado, AV; Ferreira, DG; Monteiro, IObjectives: Ocrelizumab demonstrated significant clinical benefit for the treatment of relapsing (RMS) and primary progressive (PPMS) multiple sclerosis (MS), an incurable disease characterized by disability progression. This study evaluated the clinical and economic impact of ocrelizumab relative to current clinical practice, including other disease-modifying therapies (DMT), available in Portugal. Methods: Ma...
Fingolimod Treatment Modulates PPARγ and CD36 Gene Expression in Women with Mul...
Ferret-Sena, V; Capela, C; Macedo, A; Salgado, AV; Derudas, B; Staels, B; Sena, AFingolimod is an oral immunomodulatory drug used in the treatment of multiple sclerosis (MS) that may change lipid metabolism. Peroxisome proliferator-activated receptors (PPAR) are transcription factors that regulate lipoprotein metabolism and immune functions and have been implicated in the pathophysiology of MS. CD36 is a scavenger receptor whose transcription is PPAR regulated. The objective of this study w...
Prolonged-release fampridine in multiple sclerosis: clinical data and real-worl...
Albrecht, P; Bjørnå, K; Brassat, D; Farrell, R; Feys, P; Hobart, J; Hupperts, R; Linnebank, M; Magdič, J; Oreja-Guevara, C; Pozzilli, C; Salgado, AVProlonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4-7. Recent responder subgroup analyses in the phase III ENHANCE study show a large effect size in terms of an increase of 20.58 points on the patient...
Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in...
Hupperts, R; Becker, V; Friedrich, J; Gobbi, C; Salgado, AV; Sperling, B; You, XOBJECTIVES: The 12-month observational PERSIST study (NCT01405872) evaluated adherence associated with the intramuscular IFNβ-1a (i.m. IFN-β-1a) autoinjector pen in multiple sclerosis (MS) patients. METHODS: MS patients initiating i.m. IFN-β-1a autoinjector treatment were prospectively assessed for physician-reported persistence (percentage of patients remaining on therapy) and patient-reported outcomes, includ...
Citicoline in the treatment of acute ischaemic stroke: an international, random...
Dávalos, A; Alvarez-Sabin, J; Castillo, J; Diez-Tejedor, E; Ferro, J; Martinez-Vila, E; Serena, J; Segura, T; Cruz, V; Masjuan, J; Cobo, E; Secades, JBACKGROUND: Citicoline is approved in some countries for the treatment of acute ischaemic stroke. The drug has shown some evidence of efficacy in a pooled analysis. We sought to confirm the efficacy of citicoline in a larger trial. METHODS: We undertook a randomised, placebo-controlled, sequential trial in patients with moderate-to-severe acute ischaemic stroke admitted at university hospitals in Germany, Portu...
Diagnosis of stroke by the nonneurologist: a validation study.
Ferro, J; Pinto, A; Falcão, I; Rodrigues, G; Ferreira, J; Falcão, F; Azevedo, E; Canhão, P; Melo, T; Rosas, MJ; Oliveira, V; Salgado, AVBACKGROUND AND PURPOSE: The first medical contact of an acute stroke victim is often a nonneurologist. Validation of stroke diagnosis made by these medical doctors is poorly known. The present study seeks to validate the stroke diagnoses made by general practitioners (GPs) and hospital emergency service physicians (ESPs). METHODS: Validation through direct interview and examination by a neurologist was performe...